Danaher price to free cash flow DHR

Market value divided by free cash flow over the last twelve months, since 2010.

Today, Oct 23, 2026: 29.6×
10-year median: 25.8×
Against its 10-year history: 75th; percentile: 0 is its lowest day, 100 its highest
10-year range: 13.5× to 39.2×
Peer median: 35.2×

Danaher's price to free cash flow is 29.6× as of Oct 23, 2026.

That is above its ten-year median of 25.8×, higher than on 75% of days in the last ten years.

Over that time it ranged from 13.5× in Nov 2016 to 39.2× in Aug 2024.

The median for 10 diagnostics and research stocks of a similar size is 35.2×.

Price to free cash flow over time

median 25.8×

The dashed line is the 10-year median and the shaded band the middle half of its days.

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	29.6×	21.7×	33.6×
2025	32.4×	24.5×	35.4×
2024	33.3×	24.6×	39.2×
2023	25.2×	20.3×	25.2×
2022	24.2×	21.5×	27.2×
2021	29.5×	24.1×	34.4×
2020	31.0×	23.0×	38.1×
2019	29.1×	20.8×	29.1×
2018	21.1×	19.4×	23.9×
2017	21.4×	14.1×	21.9×
2016	13.7×	12.2×	14.6×
2015	13.4×	11.9×	14.0×
2014	13.6×	11.3×	13.6×
2013	12.9×	9.0×	12.9×
2012	8.6×	8.1×	11.7×
2011	10.4×	9.3×	13.0×
2010	11.6×	9.2×	11.6×

Against its peers

Companies in Medical - Diagnostics & Research nearest Danaher's size, closest first, today.

Company	Price to free cash flow
DHRDanaher	29.6×
TMOThermo Fisher Scientific	n/m
AAgilent Technologies	38.5×
IQVIQVIA	21.1×
WATWaters	112×
IDXXIDEXX Laboratories	35.2×
ILMNIllumina	43.7×
MTDMettler-Toledo International	38.7×
DGXQuest Diagnostics	19.8×
LHLabcorp	23.1×
MEDPMedpace	26.4×
Peer median	35.2×

What the price to free cash flow tells you

Market value divided by free cash flow: the cash left after running the business and paying for equipment. Cash is harder to manage than accounting earnings, so many investors trust this more than PE.

Lumpy: a big year of building factories drops cash flow and inflates the ratio without the business getting worse.

More on Danaher

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.